Literature DB >> 33591475

Comparable neointimal healing in patients with stable coronary lesions and acute coronary syndrome: 3-month optical coherence tomography analysis.

Yuma Hamanaka1, Yohei Sotomi2,3, Tomoaki Kobayashi1, Takashi Omatsu1, Jouke Dijkstra4, Yasushi Sakata5, Atsushi Hirayama1, Akio Hirata1, Yoshiharu Higuchi1.   

Abstract

We aimed to assess a possible difference of the neointimal coverage status and its quality after implantation of the current-generation metallic stents in patients with acute coronary syndrome (ACS) vs. stable coronary lesions (non-ACS). We comprehensively analyzed three prospective single-center observational studies RESTORE (UMIN000033009), HEAL-BioFreedom (UMIN000029692), and HEAL-BioFreedom ACS (UMIN000034769). All patients who received successful optical coherence tomography (OCT) examination at planned 3-month follow-up after stent implantation were analyzed. Study population was divided into two groups, ACS vs. non-ACS groups. We evaluated standard OCT variables, coverage percent, and the quantitative light property values including light intensity, attenuation, and backscatter of neointima. A total of 177 lesions from 154 patients (ACS 44 lesions vs. non-ACS 133 lesions) were analyzed. At 3-month follow-up, coverage percent (ACS 91.5  ±  9.5% vs. non-ACS 91.8  ±  9.0%, P = 0.722) and neointimal thickness (ACS 59.5  ±  32.3 µm vs. non-ACS 58.2  ±  32.3 µm, P = 0.760) did not significantly differ. Light property values were similar between both groups (light intensity 159.29  ±  72.20 vs. 159.45   ± 63.78, P = 0.654; light attenuation 0.88  ±  0.26 vs. 0.87   ±  0.24 m-1, P = 0.988; backscatter 4.86   ±  0.58 vs. 4.83   ±  0.57, P = 0.812). The similarity of the neointimal quality in ACS and non-ACS patients was consistent across the 6 different types of current-generation metallic stents (P for interaction  > 0.05). Our findings suggested the comparable neointimal characteristics 3 months after implantation of the current-generation metallic stents in patients with ACS and stable coronary lesions by quantitative OCT methodology.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature.

Entities:  

Keywords:  Acute coronary syndrome; Drug-eluting stent; Light property analysis; Optical coherence tomography

Year:  2021        PMID: 33591475     DOI: 10.1007/s10554-021-02189-0

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  24 in total

1.  Ex vivo assessment of neointimal characteristics after drug-eluting stent implantation: Optical coherence tomography and histopathology validation study.

Authors:  Takahiro Imanaka; Kenichi Fujii; Hiroyuki Hao; Masahiko Shibuya; Ten Saita; Rika Kawakami; Masashi Fukunaga; Kenji Kawai; Hiroto Tamaru; Kojiro Miki; Tetsuo Horimatsu; Akinori Sumiyoshi; Machiko Nishimura; Seiichi Hirota; Tohru Masuyama; Masaharu Ishihara
Journal:  Int J Cardiol       Date:  2016-07-09       Impact factor: 4.164

2.  Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.

Authors:  Philip Urban; Ian T Meredith; Alexandre Abizaid; Stuart J Pocock; Didier Carrié; Christoph Naber; Janusz Lipiecki; Gert Richardt; Andres Iñiguez; Philippe Brunel; Mariano Valdes-Chavarri; Philippe Garot; Suneel Talwar; Jacques Berland; Mohamed Abdellaoui; Franz Eberli; Keith Oldroyd; Robaayah Zambahari; John Gregson; Samantha Greene; Hans-Peter Stoll; Marie-Claude Morice
Journal:  N Engl J Med       Date:  2015-10-14       Impact factor: 91.245

3.  Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial.

Authors:  Yohei Sotomi; Yoshinobu Onuma; Shengnan Liu; Taku Asano; Jeroen Eggermont; Yuki Katagiri; Rafael Cavalcante; Robbert J de Winter; Joanna J Wykrzykowska; Salvatore Brugaletta; Lorenz Räber; Manel Sabaté; Stephan Windecker; Jouke Dijkstra; Patrick W Serruys
Journal:  EuroIntervention       Date:  2018-08-20       Impact factor: 6.534

Review 4.  Imaging assessment of bioresorbable vascular scaffolds.

Authors:  Yohei Sotomi; Pannipa Suwannasom; Erhan Tenekecioglu; Carlos Collet; Shimpei Nakatani; Takayuki Okamura; Takashi Muramatsu; Yuki Ishibashi; Hiroki Tateishi; Yosuke Miyazaki; Taku Asano; Yuki Katagiri; Constantin von Zur Muehlen; Kengo Tanabe; Ken Kozuma; Yukio Ozaki; Patrick W Serruys; Yoshinobu Onuma
Journal:  Cardiovasc Interv Ther       Date:  2017-08-01

5.  Neointimal characteristics comparison between biodegradable-polymer and durable-polymer drug-eluting stents: 3-month follow-up optical coherence tomography light property analysis from the RESTORE registry.

Authors:  Tomoaki Kobayashi; Yohei Sotomi; Satoshi Suzuki; Yuma Hamanaka; Shimpei Nakatani; Jouke Dijkstra; Yoshinobu Onuma; Patrick W Serruys; Yasushi Sakata; Atsushi Hirayama; Yoshiharu Higuchi
Journal:  Int J Cardiovasc Imaging       Date:  2019-10-31       Impact factor: 2.357

6.  Detailed comparison of intra-stent conditions 12 months after implantation of everolimus-eluting stents in patients with ST-segment elevation myocardial infarction or stable angina pectoris.

Authors:  Taiji Mizoguchi; Takahiro Sawada; Toshiro Shinke; Shinichiro Yamada; Hiroshi Okamoto; Su-Shiku Kim; Akira Takarada; Yoshinori Yasaka
Journal:  Int J Cardiol       Date:  2013-12-21       Impact factor: 4.164

7.  Early vessel healing after implantation of biodegradable-polymer and durable-polymer drug-eluting stent: 3-month angioscopic evaluation of the RESTORE registry.

Authors:  Satoshi Suzuki; Yohei Sotomi; Tomoaki Kobayashi; Yuma Hamanaka; Shimpei Nakatani; Ichiro Shiojima; Yasushi Sakata; Atsushi Hirayama; Yoshiharu Higuchi
Journal:  Int J Cardiovasc Imaging       Date:  2019-03-14       Impact factor: 2.357

8.  Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome –HATTRICK-OCT trial.

Authors:  Pasi P Karjalainen; Ville Varho; Wail Nammas; Jussi Mikkelsson; Mikko Pietilä; Antti Ylitalo; Juhani K E Airaksinen; Jussi Sia; Kai Nyman; Fausto Biancari; Tuomas Kiviniemi
Journal:  Circ J       Date:  2014-12-15       Impact factor: 2.993

9.  Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).

Authors:  Bernard Chevalier; Pieter C Smits; Didier Carrié; Julinda Mehilli; Ad J Van Boven; Evelyn Regar; Fadi J Sawaya; Daniel Chamié; Adriaan O Kraaijeveld; Thomas Hovasse; Georgios J Vlachojannis
Journal:  Circ Cardiovasc Interv       Date:  2017-12       Impact factor: 6.546

10.  Early vascular healing after titanium-nitride-oxide-coated stent versus platinum-chromium everolimus-eluting stent implantation in patients with acute coronary syndrome.

Authors:  Ville Varho; Tuomas O Kiviniemi; Wail Nammas; Jussi Sia; Hannu Romppanen; Mikko Pietilä; Juhani K Airaksinen; Jussi Mikkelsson; Petri Tuomainen; Anssi Perälä; Pasi P Karjalainen
Journal:  Int J Cardiovasc Imaging       Date:  2016-04-13       Impact factor: 2.357

View more
  2 in total

1.  Prevalence of the Japanese high bleeding risk criteria and its prognostic significance for fatal bleeding in patients with acute myocardial infarction.

Authors:  Yohei Sotomi; Shungo Hikoso; Daisaku Nakatani; Shinichiro Suna; Tomoharu Dohi; Hiroya Mizuno; Katsuki Okada; Hirota Kida; Bolrathanak Oeun; Akihiro Sunaga; Taiki Sato; Tetsuhisa Kitamura; Yasuhiko Sakata; Hiroshi Sato; Masatsugu Hori; Issei Komuro; Yasushi Sakata
Journal:  Heart Vessels       Date:  2021-03-20       Impact factor: 2.037

2.  Practical Assessment of the Tradeoff between Fatal Bleeding and Coronary Thrombotic Risks using the Academic Research Consortium for High Bleeding Risk Criteria.

Authors:  Yohei Sotomi; Shungo Hikoso; Daisaku Nakatani; Tomoharu Dohi; Hiroya Mizuno; Katsuki Okada; Hirota Kida; Bolrathanak Oeun; Akihiro Sunaga; Taiki Sato; Tetsuhisa Kitamura; Yasuhiko Sakata; Hiroshi Sato; Masatsugu Hori; Issei Komuro; Yasushi Sakata
Journal:  J Atheroscler Thromb       Date:  2021-09-15       Impact factor: 4.394

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.